Simple Summary The purpose of the CET-MET trial was to find a new platinum-based
chemotherapy regimen in combination with cetuximab for relapsed or metastatic squamous …

In recent years, a large oncological focus was set on the venue of immunotherapy in the
systemic treatment of recurrent/metastatic squamous cell carcinoma of the head and neck …

Background: Pembro showed antitumor activity and manageable toxicity in R/M HNSCC in
an extended phase 1b study. KEYNOTE-040 (NCT02252042) was a global, open-label …

Background Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC),
with programmed cell death ligand 1 (PD-L1) expression associated with improved …

Background/Aim: Head and neck cancers account for 8% of all cancer cases worldwide.
However, identifying the optimal treatment for recurrent or metastatic head and neck cancer …

Burtness et al. recently published the landmark Keynote-48 study, demonstrating a survival
benefit for pembrolizumab monotherapy and pembrolizumab/chemotherapy, compared with …

Background: R/M HNSCC patients (pts) who have progressed on platinum-based
chemotherapy have a poor prognosis and limited therapeutic options. Programmed cell …

Background In the phase III KEYNOTE-048 study, pembro significantly prolonged OS vs E in
patients (pts) with PD-L1 combined positive score (CPS)≥ 20 and CPS≥ 1 and had …

Background/Aim: Pembrolizumab exhibits anticancer efficacy in platinum-sensitive or
platinum-unfit patients with recurrent/metastatic squamous cell carcinoma of the head and …

5505 Background: Patients with R&M SCCHN have a poor prognosis. Patients failing first-
line therapy have few therapeutic options. Cetuximab (Erbitux) is an IgG1 monoclonal …